A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy

Trial Profile

A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2013

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Wyeth
  • Most Recent Events

    • 11 Jun 2009 Results presented at the 27th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID), according to a Wyeth media release.
    • 12 Aug 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
    • 17 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top